Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP948877.RAbPHw5Iz3-acxJfsSHd-jS35kEiD9uBkZ3LR7s8ml5aI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP948877.RAbPHw5Iz3-acxJfsSHd-jS35kEiD9uBkZ3LR7s8ml5aI130_assertion type Assertion NP948877.RAbPHw5Iz3-acxJfsSHd-jS35kEiD9uBkZ3LR7s8ml5aI130_head.
- NP948877.RAbPHw5Iz3-acxJfsSHd-jS35kEiD9uBkZ3LR7s8ml5aI130_assertion description "[The recognition of the impact of single-nucleotide polymorphisms (SNPs) of the genes interleukin 28B (IL28B), inosine triphosphatase (ITPA) and low-density lipoprotein cholesterol receptor (LDLR) may lead to refinements in the pharmacogenomic prediction of antiviral response and drug-related toxicities and favour the discovery of new therapeutic targets for hepatitis C. Although the relevance of host genetics may be less in the setting of very potent new direct-acting antivirals (DAAs), genetic markers may continue to aid decision making regarding the length of therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP948877.RAbPHw5Iz3-acxJfsSHd-jS35kEiD9uBkZ3LR7s8ml5aI130_provenance.
- NP948877.RAbPHw5Iz3-acxJfsSHd-jS35kEiD9uBkZ3LR7s8ml5aI130_assertion evidence source_evidence_literature NP948877.RAbPHw5Iz3-acxJfsSHd-jS35kEiD9uBkZ3LR7s8ml5aI130_provenance.
- NP948877.RAbPHw5Iz3-acxJfsSHd-jS35kEiD9uBkZ3LR7s8ml5aI130_assertion SIO_000772 22194301 NP948877.RAbPHw5Iz3-acxJfsSHd-jS35kEiD9uBkZ3LR7s8ml5aI130_provenance.
- NP948877.RAbPHw5Iz3-acxJfsSHd-jS35kEiD9uBkZ3LR7s8ml5aI130_assertion wasDerivedFrom befree-2016 NP948877.RAbPHw5Iz3-acxJfsSHd-jS35kEiD9uBkZ3LR7s8ml5aI130_provenance.
- NP948877.RAbPHw5Iz3-acxJfsSHd-jS35kEiD9uBkZ3LR7s8ml5aI130_assertion wasGeneratedBy ECO_0000203 NP948877.RAbPHw5Iz3-acxJfsSHd-jS35kEiD9uBkZ3LR7s8ml5aI130_provenance.